Justus Thomas, MD
Ophthalmology · Kingwood, TXNPI 1316051907
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,827 of the $13,737 with a category attached, or 71.5%. 26 manufacturers reported payments, led by AbbVie at 38.7% of the total. Reporting peaked in 2019 at $3,282 and has fallen 58.2% since, to $1,370 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 366 payments — averaging $37.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Alcon$3K
- Carl Zeiss Meditec, Inc.$846
- Oyster Point Pharma, Inc.$604
- Bausch & Lomb Americas Inc.$569
- Novartis$463
- plus $3K from 20 others
Across 1 payment — averaging $687.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$687
What the payments were for
- Consulting fees$3,12523%
- Travel & lodging$7505%
- Food & beverage$9,82772%
- Gifts$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 124 | $5,322 |
| Alcon | 56 | $3,077 |
| Carl Zeiss Meditec, Inc. | 13 | $846 |
| Oyster Point Pharma, Inc. | 26 | $604 |
| Bausch & Lomb Americas Inc. | 17 | $569 |
| Novartis | 26 | $463 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 24 | $378 |
| Carl Zeiss Meditec USA, Inc. | 4 | $375 |
| Glaukos Corporation | 4 | $343 |
| Amgen(2 entities) | 13 | $312 |
| Harrow Eye, LLC | 11 | $280 |
| Sun Pharmaceutical Industries Inc. | 12 | $227 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $165 |
| Tarsus Pharmaceuticals, Inc. | 6 | $163 |
| Ocular Therapeutix, Inc. | 2 | $138 |
| Kala Pharmaceuticals, Inc. | 6 | $125 |
| Staar Surgical Company | 1 | $95 |
| Eyevance Pharmaceuticals LLC | 2 | $41 |
| Aerie Pharmaceuticals, Inc. | 2 | $40 |
| Biotissue Holdings Inc. | 2 | $39 |
| Dompe US, Inc. | 2 | $35 |
| Rayner Intraocular Lenses Limited | 2 | $32 |
| Rxsight Inc | 2 | $30 |
| Shire North American Group Inc | 1 | $17 |
| Astellas Pharma US Inc | 1 | $13 |
| Lensar, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESTASIS$2,250
- RESTASIS MULTIDOSE$875
- ARTEVO 800$446
- VisuMax$398
- DEXTENZA$359
- Clareon$274
- LenSx$269
- VUITY$247
- DAILIES$209
- MIEBO$149
- XIIDRA$149
- VYZULTA$149
- enVista MX60 IOL$149
- STELLARIS ELITE$149
- Clareon PanOptix Pro$148
- ReSTOR$141
- Precision 1$125
- TRYPTYR$122
- ReSure Sealant$120
- KXL System$118
How this compares
$13,737 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 573 | $617,591 |
| Cyclosporine | 228 | $117,084 |
| LumiganBimatoprost | 204 | $100,513 |
| XiidraLifitegrast | 82 | $89,973 |
| XdemvyLotilaner | 33 | $59,130 |
| TyrvayaVarenicline Tartrate | 41 | $27,482 |
| Prednisolone Acetate | 649 | $27,378 |
| MieboPerfluorohexyloctane/Pf | 29 | $26,972 |
| CequaCyclosporine | 26 | $23,094 |
| MoxifloxacinMoxifloxacin Hcl | 823 | $17,380 |
| Loteprednol Etabonate | 63 | $11,138 |
| Alphagan PBrimonidine Tartrate | 17 | $10,698 |
| Ketorolac Tromethamine | 646 | $8,974 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $8,469 |
| Tobradex StTobramycin/Dexamethasone | 26 | $6,045 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $5,322 | $737,272812 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $569 | $116,945111 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $163 | $59,13033 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $604 | $27,48241 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $227 | $23,09426 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm, Besivance | $378 | $17,97092 claims |
| Eyevance Pharmaceuticals LLCTobradex St, Flarex | $41 | $7,39337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Kingwood
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Ashkan AbbeyDallas$559K
- Stephen SladeHouston$530K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.